518 related articles for article (PubMed ID: 33384602)
1. Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson's Disease.
Patricio F; Morales-Andrade AA; Patricio-Martínez A; Limón ID
Front Pharmacol; 2020; 11():595635. PubMed ID: 33384602
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Junior NCF; Dos-Santos-Pereira M; Guimarães FS; Del Bel E
Neurotox Res; 2020 Jan; 37(1):12-29. PubMed ID: 31637586
[TBL] [Abstract][Full Text] [Related]
3. GPR55: A therapeutic target for Parkinson's disease?
Celorrio M; Rojo-Bustamante E; Fernández-Suárez D; Sáez E; Estella-Hermoso de Mendoza A; Müller CE; Ramírez MJ; Oyarzábal J; Franco R; Aymerich MS
Neuropharmacology; 2017 Oct; 125():319-332. PubMed ID: 28807673
[TBL] [Abstract][Full Text] [Related]
4. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
Espejo-Porras F; Fernández-Ruiz J; Pertwee RG; Mechoulam R; García C
Neuropharmacology; 2013 Dec; 75():155-63. PubMed ID: 23924692
[TBL] [Abstract][Full Text] [Related]
5. Neuromodulation in Parkinson's disease targeting opioid and cannabinoid receptors, understanding the role of NLRP3 pathway: a novel therapeutic approach.
Alam MR; Singh S
Inflammopharmacology; 2023 Aug; 31(4):1605-1627. PubMed ID: 37318694
[TBL] [Abstract][Full Text] [Related]
6. µ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease.
Bezard E; Li Q; Hulme H; Fridjonsdottir E; Nilsson A; Pioli E; Andren PE; Crossman AR
J Neurosci; 2020 Aug; 40(35):6812-6819. PubMed ID: 32690616
[TBL] [Abstract][Full Text] [Related]
7. Expression of GPR55 and either cannabinoid CB
Martínez-Pinilla E; Rico AJ; Rivas-Santisteban R; Lillo J; Roda E; Navarro G; Lanciego JL; Franco R
Brain Struct Funct; 2020 Sep; 225(7):2153-2164. PubMed ID: 32691218
[TBL] [Abstract][Full Text] [Related]
8. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
[TBL] [Abstract][Full Text] [Related]
9. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
van der Stelt M; Fox SH; Hill M; Crossman AR; Petrosino S; Di Marzo V; Brotchie JM
FASEB J; 2005 Jul; 19(9):1140-2. PubMed ID: 15894565
[TBL] [Abstract][Full Text] [Related]
10. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
[TBL] [Abstract][Full Text] [Related]
11. Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?
Crippa JAS; Hallak JEC; Zuardi AW; Guimarães FS; Tumas V; Dos Santos RG
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):121-133. PubMed ID: 30706171
[TBL] [Abstract][Full Text] [Related]
12. GPR3 and GPR6, novel molecular targets for cannabidiol.
Laun AS; Song ZH
Biochem Biophys Res Commun; 2017 Aug; 490(1):17-21. PubMed ID: 28571738
[TBL] [Abstract][Full Text] [Related]
13. GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol.
Laun AS; Shrader SH; Brown KJ; Song ZH
Acta Pharmacol Sin; 2019 Mar; 40(3):300-308. PubMed ID: 29941868
[TBL] [Abstract][Full Text] [Related]
14. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
Morin N; Di Paolo T
Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
[TBL] [Abstract][Full Text] [Related]
15. Biological bases for a possible effect of cannabidiol in Parkinson's disease.
Ferreira-Junior NC; Campos AC; Guimarães FS; Del-Bel E; Zimmermann PMDR; Brum Junior L; Hallak JE; Crippa JA; Zuardi AW
Braz J Psychiatry; 2020 Apr; 42(2):218-224. PubMed ID: 31314869
[TBL] [Abstract][Full Text] [Related]
16. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
Duty S; Jenner P
Br J Pharmacol; 2011 Oct; 164(4):1357-91. PubMed ID: 21486284
[TBL] [Abstract][Full Text] [Related]
17. Parkinson's disease related alterations in cannabinoid transmission.
Soti M; Ranjbar H; Kohlmeier KA; Shabani M
Brain Res Bull; 2022 Jan; 178():82-96. PubMed ID: 34808322
[TBL] [Abstract][Full Text] [Related]
18. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Urs NM; Bido S; Peterson SM; Daigle TL; Bass CE; Gainetdinov RR; Bezard E; Caron MG
Proc Natl Acad Sci U S A; 2015 May; 112(19):E2517-26. PubMed ID: 25918399
[TBL] [Abstract][Full Text] [Related]
19. Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson's and Alzheimer's Diseases: a Review.
Cooray R; Gupta V; Suphioglu C
Mol Neurobiol; 2020 Nov; 57(11):4878-4890. PubMed ID: 32813239
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease.
Han QW; Yuan YH; Chen NH
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109745. PubMed ID: 31442553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
